HKU Scholars Hub: Browsing DSpace

Browsing by Author Agarwal, K

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 20 of 41 next >

Title	Author(s)	Issue Date	Views
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection Journal:Journal of Hepatology	Agarwal, K Brunetto, M Seto, WKW Lim, YS Fung, S Marcellin, P Ahn, SH Izumi, N Chuang, WL Bae, H Sharma, M Janssen, H Pan, C Celen, MK Furusyo, N Shalimar, D Yoon, KT Trinh, H Chan, HL	2018	104
A phase 1 study evaluating the neutralizing, vaccinal monoclonal antibody VIR-3434 in participants with chronic hepatitis B virus infection Proceeding/Conference:Journal of Hepatology	Agarwal, K Yuen, RMF Wedemeyer, H Cloutier, D Shen, L Arizpe, A Pang, P Tay, C Gupta, SV Cathcart, A Gane, E	2021	27
Analysis of longer-term safety profile of the hepatitis B virus core inhibitor ABI-H0731 in an open label extension study Proceeding/Conference:Hepatology	Jacobson, IM Ma, X Nguyen, T Schiff, ER Yuen, RMF Hann, HWL Sulkowski, MS Nahass, RG Ramji, A Agarwal, K Park, JS Ayoub, WS Gane, EJ Knox, S Alves, K Li, YF Stamm, LM Weilert, F Bennett, M Han, SHB Ravendhran, N Chan, S Kwo, PY Elkhashab, M Hassanein, T Fung, SK Bae, H Lalezari, JP Dieterick, DT	2020	12
Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-positive chronic hepatitis B infection in a long-term extension study Proceeding/Conference:Journal of Hepatology	Yuen, RMF Agarwal, K Ma, X Nguyen, T Schiff, ER Hann, HW Dieterich, D Nahass, R Park, J Chan, S Han, SH Gane, E Bennett, M Alves, K Zayed, H Huang, Q Colonno, R Knox, S Stamm, L Bonacini, M Jacobson, I Ayoub, W Weilert, F Ravendhran, N Ramji, A Kwo, P Elkhashab, M Hassanein, T Bae, H Lalezari, J Fung, S Sulkowski, M	2020	40
Antiviral activity, pharmacokinetics and safety of the second-generation hepatitis B core inhibitor ABI-H2158 in Phase 1b study of patients with HBeAg-positive chronic hepatitis B infection Proceeding/Conference:Journal of Hepatology	Agarwal, K Niu, J Ding, Y Gane, E Nguyen, T Alves, K Evanchick, M Zayed, H Huang, Q Knox, S Stamm, L Colonno, R Hassanein, T Kim, DJ Lim, YS Yuen, RMF	2020	36
Continued therapy with ABI-H0731+NRTI results in sequential reduction/loss of HBV DNA, HBV RNA, HBeAg, HBcrAg and HBsAg in HBeAg positive patients Proceeding/Conference:Hepatology	Sulkowski, MS Agarwal, K Fung, SK Yuen, RMF Ma, XL Lalezari, JP Nguyen, TT Bae, HS Schiff, ER Hassanein, T Hann, HWL Elkhashab, M Dieterich, DT Kwo, PY Nahass, R Ramji, A Park, JS Ravendhran, N Chan, S Weilert, F Han, SHB Ayoub, WS Gane, EJ Jacobson, IM Bennett, M Bonacini, M Zayed, H Alves, K Huey, V Huang, Q Ruby, E Qiang, DM Knox, S Colonno, R	2019	54
Final results of a phase 1b 28-day study of ABI-H0731, a novel core inhibitor, in non-cirrhotic viremic subjects with chronic hepatitis B Journal:Hepatology	Yuen, RMF Agarwal, K Gane, EJ Schwabe, .C Ahn, SH Kim, DJ Lim, YS Cheng, W Sievert, W Visvanathan, K Ruby, E Liaw, S Yan, R Connelly, E Cai, DW Huang, Q Colonno, R Lopatin, UA	2018	50
HBsAg loss after nucleo(s)tide analogue withdrawal: relationship with viral antigen levels and hbv genotype Proceeding/Conference:Poster presentation at the AASLD The Liver Meeting, November 12-15. 2021. Hepatology	Sonneveld, MJ Chiu, S-M Park, JY Kaewdech, A Seto, WKW Tanaka, Y Carey, I Papatheodoridi, M Van Bömmel, F Brakenhoff, S Berg, T Zoulim, F Ahn, SH Dalekos, GN Erler, NS Zu Siederdissen, CN Wedemeyer, H Cornberg, M Yuen, RMF Agarwal, K Boonstra, A Buti, M Piratvisuth, T Papatheodoridis, G Chen, CH Maasoumy, B CREATE study group,	2021
HBV DNA AND HBSAG LEVELS AT 24 WEEKS OFF-TREATMENT PREDICT CLINICAL RELAPSE AND HBSAG LOSS IN HBEAG NEGATIVE PATIENTS WHO DISCONTINUED ANTIVIRAL THERAPY Journal:Gastroenterology	Sonneveld, MJ Chiu, S-M Park, JY Brakenhoff, SM Kaewdech, A Seto, WK Tanaka, Y Carey, I Papatheodoridi, M Colombatto, P Van Bömmel, F Janssen, HL Berg, T Zoulim, F Ahn, SH Dalekos, GN Erler, NS Brunetto, M Wedemeyer, H Cornberg, M Yuen, MF Agarwal, K Boonstra, A Buti, M Piratvisuth, T Papatheodoridis, G Chen, C-H Maasoumy, B	26-Sep-2023
HBV PGRNA and DNA both rebound immediately following discontinuation of the core inhibitor vebicorvir despite continued nrti treatment in patients with HBeAg positive chronic hepatitis B virus infection: findings from a phase 2 open label study Proceeding/Conference:Oral presentation at the AASLD The Liver Meeting, November 12-15. 2021. Hepatology	Yuen, RMF Ma, XL Hassanein, TI Kwo, PY Ma, J Li, L Kitrinos, K Knox, SJ Stamm, LM Bae, H Sulkowski, MS Elkhashab, M Agarwal, K	2021
Hepatitis B surface antigen (HBsAg) reductions following administration of a single dose of VIR-3434, an investigational, neutralizing, vaccinal monoclonal antibody: first experience in participants with high HBsAg burden Proceeding/Conference:Hepatology International	Yuen, MF Agarwal, K Wedemeyer, H Cloutier, D Shen, L Arizpe, A Hassani, A Gupta, SV Hwang, C Gane, E Agarwal, K	31-Mar-2023
IMPACT OF TREATMENT WITH TENOFOVIR ALAFENAMIDE (TAF) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) ON HEPATOCELLULAR CARCINOMA (HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) Proceeding/Conference:Hepatology	Lim, Y Chan, HLY Seto, WKW Ning, Q Agarwal, K Janssen, HL Pan, CQ Chuang, WL Izumi, N Fung, SK Shalimar,Brunetto, MR Flaherty, JF Mo, S Cheng, C Lin, L Gaggar, A Subramanian, M Marcellin, P Gane, EJ Hou, J Buti, M	2019	120
Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients Proceeding/Conference:Journal of Hepatology	Ma, XL Lalezari, J Nguyuen, T Bae, Ho Schiff, ER Fung, S Yuen, RMF Hassanein, T Hann, HW Elkhashab, M Dieterich, D Sulkowski, M Kwo, P Nahass, R Agarwal, K Ramji, A Park, J Ravendhran, N Chan, S Weilert, F Han, SH Ayoub, W Gane, E Jacobson, I Bennett, M Huang, Q Yan, R Huey, V Ruby, E Liaw, S Colonno, R Lopatin, U	2019	74
Interim safety, tolerability pharmacokinetics, and antiviral activity of ABI-H0731, a novel core protein allosteric modulator, in healthy volunteers and non-cirrhotic viremic subjects with chronic hepatitis B Proceeding/Conference:Journal of Hepatology	Yuen, RMF Agarwal, K Gane, E Schwabe, C Cheng, W Sievert, W Kim, DJ Ahn, SH Lim, YS Visvanathan, K Ruby, E Liaw, S Colonno, R Lopatin, U	2018	110
International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates Journal:Transplantation	Terrault, NA McCaughan, GW Curry, MP Gane, E Fagiuoli, S Fung, JYY Agarwal, K Lilly, L Strasser, SI Brown, KA Gadano, A Kwo, PY Burra, P Samuel, D Charlton, M Pessoa, MG Berenguer, M	2017	93
International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients Journal:Transplantation	Terrault, N Berenguer, M Strasser, SI Gadano, A Lilly, L Samuel, D Kwo, PY Agarwal, K Curry, MP Faguioli, S Fung, JYY Gane, E Brown, KA Burra, P Charlton, M Pessoa, MG McCaughan, GW	2017	50
Low HBcrAg and HBsAg levels identify patients most likely to achieve sustained response after nucleos(t)ide analogue cessation: results from a global individual patient data meta-analysis (create study) Proceeding/Conference:Journal of Hepatology	Sonneveld, M Park, JY Seto, WKW Tanaka, Y Carey, I Papatheodoridi, M Zoulim, F Ahn, SH Dalekos, G Hoener zu Siederdissen, C Cornberg, M Yuen, RMF Agarwal, K Boonstra, A Buti, M Papatheodoridis, G Maasoumy, B	2020	31
Lower Pre-Treatment HBV DNA Levels Are Associated With Better Off-Treatment Outcomes After Nucleo(S)Tide Analogue Withdrawal In Patients With Chronic Hepatitis B Proceeding/Conference:Hepatology	Sonneveld, MJ Chiu, SM Park, JY Brakenhoff, S Kaewdech, A Seto, WK Tanaka, Y Carey, I Papatheodoridi, M Colombatto, P Van Bommel, F Berg, T Zoulim, F Ahn, SH Dalekos, GN Erler, NS Brunetto, M Wedemeyer, H Cornberg, M Yuen, MF Agarwal, K Boonstra, A Buti, M Piratvisuth, T Papatheodoridis, GV Chen, CH Maasoumy, B	31-Oct-2022
Prediction of sustained response after nucleo(s)tide analogue cessation using HBsAg and HBcrAg levels – a multicenter study (CREATE) Proceeding/Conference:Hepatology	Sonneveld, MJ Park, JY Kaewdech, A Seto, WKW Tanaka, Y Carey, I Papatheodoridi, M Van Bömmel, F Berg, T Zoulim, F Ahn, SH Dalekos, GN Erier, NS Höner zu SiederdissenC, C Wedemeyer, H Comberg, M Yuen, RMF Agarwal, K Boonstra, A Ferret, MAB Piratvisuth, T Papatheodoridis, G Maasoumy, B CREATE study group,	2020	12
Prediction Of Sustained Response After Nucleo(s)tide Analogue Cessation Using Hbsag And Hbcrag Levels – A Multicenter Study (create) Journal:Clinical Gastroenterology and Hepatology	Sonneveld, MJ Park, JY Kaewdech, A Seto, WK Tanaka, Y Carey, I Papatheodoridi, M van Bommel, F Berg, T Zoulim, F Ahn, SH Dalekos, GN Erler, NS Honer zu Siederdissen, C Wedemeyer, H Cornberg, M Yuen, MF Agarwal, K Boonstra, A Buti, M Piratvisuth, T Papatheodoridis, G Maasoumy, B	2020	36

Showing results 1 to 20 of 41 next >